Endocrine Disruptors, The European Green Deal And The Politicization Of EU Chemical Programs
John Chave, director-general at Cosmetics Europe, says the European Commission’s plan for targeted assessment of 28 potential endocrine-disruptors in cosmetics – despite its conclusion in late 2018 that the current cosmetics regulatory framework adequately addresses endocrine-disruptor concerns – is symptomatic of a broad trend taking hold in Europe.
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Cosmetics Europe Director-General John Chave says whichever way the European Commission proceeds under its recently released sustainable chemicals strategy, there almost certainly will need to be changes to the Cosmetic Products Regulation. Chave counts the strategy among “the biggest legislative policy proposals affecting our sector probably ever.”